Trial Profile
A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTO
- Sponsors Roche
- 11 Apr 2024 Planned End Date changed from 11 Mar 2025 to 23 Sep 2025.
- 08 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2023 Status changed from active, no longer recruiting to recruiting.